A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects

This study has been completed.
Sponsor:
Information provided by:
Halozyme Therapeutics
ClinicalTrials.gov Identifier:
NCT00311519
First received: April 4, 2006
Last updated: April 5, 2006
Last verified: April 2006
  Purpose

The purpose of this research study to test the effectiveness of a study medication to increase how fast a solution called lactated Ringer’s is absorbed when put under the skin subcutaneously. The medication to be studied is an enzyme called hyaluronidase, and is a human recombinant form of the enzyme. The drug company name for this medication is Hylenex. Hylenex was currently an investigational medication at the initiation of the study, but received FDA approval during the study. An investigational medication is a medication or formulation of a medication that is not approved by the United States Food and Drug Administration for use in this country but may be used in studies such as this one.


Condition Intervention Phase
Healthy
Drug: Hylenex
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Phase IIIB Double Blind, Randomized, Placebo-Controlled, Dose-Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects

Resource links provided by NLM:


Further study details as provided by Halozyme Therapeutics:

Primary Outcome Measures:
  • Average infusion flow rate (mL/hr) derived from the time to infuse 400 mL of lactated ringers

Secondary Outcome Measures:
  • Average SC infusion rate of flow (mL/hr) derived from time required to drain 400 mL from the 500 mL infusate bag, fluid and tubing AND for the arm circumference to return to baseline
  • Flow rate determined by weight of infusate bag, fluid and tubing at specified timepoints
  • For SC infusions, change in arm circumference in three locations in the vicinity of the site of infusion
  • For SC infusions, time from the beginning of infusion until arm circumference returns to baseline
  • Subject assessment of local discomfort by placing a mark on a 0 100 mm visual analogue scale (VAS) anchored by no discomfort and worst possible discomfort
  • Local edema assessed by the Investigator on a 0-4 scale
  • Leakage of fluid at angiocatheter site assessed by the Investigator on a 0-4 scale, prior to infusion, at mid-infusion, at end of infusion, and (for SC infusions), when arm circumference returns to baseline
  • Subject’s global rank-ordered preference for infusion
  • Investigator’s global rank-ordered preference for infusion
  • Photographic images of the SC infusion sites
  • Safety and tolerability, based on adverse events and PE including vital signs

Estimated Enrollment: 50
Study Start Date: November 2005
Estimated Study Completion Date: January 2006
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Males or females aged 18 to 60 years, inclusive
  2. Agreement that there will be no fluid intake for 12 hours prior to the start of the study infusion (except sips of water to take necessary medications)
  3. Vital signs (BP, HR, RR) within normal range
  4. Metabolic panel (e.g., sodium, potassium, chloride, bicarbonate, BUN, creatinine, glucose, calcium, AST, ALT, alkaline phosphatase, total bilirubin, albumin, and total protein) within normal range within 7 days of infusion
  5. Adequate venous access in at least one forearm
  6. A negative pregnancy test (if female of child-bearing potential) within 7 days of infusion
  7. Decision-making capacity
  8. Signed, written IRB-approved informed consent

Exclusion Criteria:

  1. Extremity edema
  2. Upper extremity pathology that could interfere with study outcome (e.g., cellulitis, lymphatic disorder or prior surgery, pre-existing pain syndrome, previous mastectomy and/or axillary lymph node dissection, etc.)
  3. History of cardiovascular disease
  4. Rales on lung auscultation
  5. Known allergy to hyaluronidase or any other ingredient in the formulation of HYLENEX
  6. Known allergy to bee or vespid venom
  7. Known coagulopathy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00311519

Locations
United States, California
West Coast Clinical Trials
Long Beach, California, United States, 90806-2325
Sponsors and Collaborators
Halozyme Therapeutics
Investigators
Principal Investigator: Javier T Quesada, OD West Coast Clinical Trials
  More Information

No publications provided by Halozyme Therapeutics

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00311519     History of Changes
Other Study ID Numbers: HZ2-05-04
Study First Received: April 4, 2006
Last Updated: April 5, 2006
Health Authority: United States: Food and Drug Administration

Keywords provided by Halozyme Therapeutics:
Subcutaneous hydration
Hylenex
Hyaluronidase

ClinicalTrials.gov processed this record on July 23, 2014